Compare Dishman Pharma with Unichem Lab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs UNICHEM LAB - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA UNICHEM LAB DISHMAN PHARMA/
UNICHEM LAB
 
P/E (TTM) x 25.1 -47.3 - View Chart
P/BV x 3.3 1.2 288.4% View Chart
Dividend Yield % 0.7 1.2 55.7%  

Financials

 DISHMAN PHARMA   UNICHEM LAB
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
UNICHEM LAB
Mar-19
DISHMAN PHARMA/
UNICHEM LAB
5-Yr Chart
Click to enlarge
High Rs374292 128.2%   
Low Rs129182 70.8%   
Sales per share (Unadj.) Rs197.8167.7 118.0%  
Earnings per share (Unadj.) Rs21.2-3.6 -584.1%  
Cash flow per share (Unadj.) Rs34.75.9 584.4%  
Dividends per share (Unadj.) Rs2.004.00 50.0%  
Dividend yield (eoy) %0.81.7 47.1%  
Book value per share (Unadj.) Rs179.9372.3 48.3%  
Shares outstanding (eoy) m80.6970.38 114.6%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x1.31.4 90.0%   
Avg P/E ratio x11.9-65.3 -18.2%  
P/CF ratio (eoy) x7.239.9 18.2%  
Price / Book Value ratio x1.40.6 219.7%  
Dividend payout %9.4-110.2 -8.6%   
Avg Mkt Cap Rs m20,30616,680 121.7%   
No. of employees `0000.82.6 31.9%   
Total wages/salary Rs m5,3552,393 223.8%   
Avg. sales/employee Rs Th19,252.74,535.2 424.5%   
Avg. wages/employee Rs Th6,459.5919.8 702.3%   
Avg. net profit/employee Rs Th2,064.1-98.2 -2,101.8%   
INCOME DATA
Net Sales Rs m15,96111,801 135.3%  
Other income Rs m265984 27.0%   
Total revenues Rs m16,22612,785 126.9%   
Gross profit Rs m4,103-835 -491.5%  
Depreciation Rs m1,091674 161.9%   
Interest Rs m94475 1,255.9%   
Profit before tax Rs m2,334-600 -389.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m11 157.1%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m624-343 -181.6%   
Profit after tax Rs m1,711-256 -669.6%  
Gross profit margin %25.7-7.1 -363.4%  
Effective tax rate %26.757.3 46.7%   
Net profit margin %10.7-2.2 -495.1%  
BALANCE SHEET DATA
Current assets Rs m11,01820,384 54.1%   
Current liabilities Rs m9,5175,029 189.2%   
Net working cap to sales %9.4130.1 7.2%  
Current ratio x1.24.1 28.6%  
Inventory Days Days110105 105.5%  
Debtors Days Days35135 25.8%  
Net fixed assets Rs m16,3049,023 180.7%   
Share capital Rs m161141 114.6%   
"Free" reserves Rs m12,90726,058 49.5%   
Net worth Rs m14,51626,199 55.4%   
Long term debt Rs m4,1890-   
Total assets Rs m29,80531,496 94.6%  
Interest coverage x3.5-7.0 -49.8%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.50.4 142.9%   
Return on assets %8.9-0.6 -1,556.1%  
Return on equity %11.8-1.0 -1,208.6%  
Return on capital %17.5-2.0 -876.8%  
Exports to sales %24.869.4 35.7%   
Imports to sales %3.70-   
Exports (fob) Rs m3,9568,188 48.3%   
Imports (cif) Rs m596NA-   
Fx inflow Rs m4,9528,188 60.5%   
Fx outflow Rs m697596 116.9%   
Net fx Rs m4,2557,592 56.0%   
CASH FLOW
From Operations Rs m2,786-3,278 -85.0%  
From Investments Rs m-1,529-2,860 53.5%  
From Financial Activity Rs m-941-24 3,888.8%  
Net Cashflow Rs m316-4,690 -6.7%  

Share Holding

Indian Promoters % 61.4 50.1 122.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 15.1 24.5%  
FIIs % 12.7 3.0 423.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 31.7 69.7%  
Shareholders   46,261 20,176 229.3%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   STERLING BIOTECH  SANOFI INDIA  ALEMBIC PHARMA  ORCHID PHARMA  NOVARTIS  

Compare DISHMAN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty End Flat; Asian Paints, UPL & ITC Among Top Gainers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

UNICHEM LAB Announces Quarterly Results (1QFY20); Net Profit Up 102.2% (Quarterly Result Update)

Jul 30, 2019 | Updated on Jul 30, 2019

For the quarter ended June 2019, UNICHEM LAB has posted a net profit of Rs 5 m (up 102.2% YoY). Sales on the other hand came in at Rs 2 bn (up 15.4% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

UNICHEM LAB 2018-19 Annual Report Analysis (Annual Result Update)

Jul 4, 2019 | Updated on Jul 4, 2019

Here's an analysis of the annual report of UNICHEM LAB for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of UNICHEM LAB. Also includes updates on the valuation of UNICHEM LAB.

UNICHEM LAB Announces Quarterly Results (4QFY19); Net Profit Up 31.7% (Quarterly Result Update)

May 29, 2019 | Updated on May 29, 2019

For the quarter ended March 2019, UNICHEM LAB has posted a net profit of Rs 37 m (up 31.7% YoY). Sales on the other hand came in at Rs 3 bn (up 35.1% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

UNICHEM LAB Announces Quarterly Results (1QFY20); Net Profit Up 102.2% (Quarterly Result Update)

Jul 30, 2019 | Updated on Jul 30, 2019

For the quarter ended June 2019, UNICHEM LAB has posted a net profit of Rs 5 m (up 102.2% YoY). Sales on the other hand came in at Rs 2 bn (up 15.4% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

UNICHEM LAB 2018-19 Annual Report Analysis (Annual Result Update)

Jul 4, 2019 | Updated on Jul 4, 2019

Here's an analysis of the annual report of UNICHEM LAB for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of UNICHEM LAB. Also includes updates on the valuation of UNICHEM LAB.

More Views on News

Most Popular

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

The Worst Sector in the Market(Fast Profits Daily)

May 11, 2021

The worst sector in the stock market according to the charts.

The Key to Profit from India's EV Revolution(Profit Hunter)

May 7, 2021

Stocks you must consider investing in before buying your first electric vehicle.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA - DR. REDDYS LAB COMPARISON

COMPARE DISHMAN PHARMA WITH

MARKET STATS